Design and structure–activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases-Reference-Cited by-同舟云学术

Design and structure–activity relationship of heterocyclic analogs of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones as inhibitors of receptor tyrosine kinases

Published:2006-04 Issue:8 Volume:16 Page:2247-2251
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Frazier Kelly,Jazan Elisa,McBride Christopher M.,Pecchi Sabina,Renhowe Paul A.,Shafer Cynthia M.,Taylor Clarke,Bussiere Dirksen,He Molly Min,Jansen Johanna M.,Lapointe Gena,Ma Sylvia,Vora Jayesh,Wiesmann Marion

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference22 articles.

1. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis

2. Mechanisms of angiogenesis and arteriogenesis

3. Vascular Endothelial Growth Factor Signaling Pathway as an Emerging Target in Hematologic Malignancies

4. Receptor tyrosine kinases as targets for anticancer drugs

5. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Radical Annulation of 2-Cyanoaryl Acrylamides via C═C Double Bond Cleavage: Access to Amino-Substituted 2-Quinolones;Organic Letters;2021-07-27

2. Chemistry and Applications of 4-Hydroxyquinolin-2-one and Quinoline-2,4-dionebased Compounds;Current Organic Chemistry;2017-10-09

3. Synthesis of new pyrido[2′,3′:3,4]pyrazolo[5,1-c]-[1,2,4]triazin-4(6H)-one derivatives;Russian Chemical Bulletin;2017-06

4. Functionalized Benzimidazole Scaffolds: Privileged Heterocycle for Drug Design in Therapeutic Medicine;Archiv der Pharmazie;2016-05-23

5. Part I. Synthesis, biological evaluation and docking studies of new 2-furylbenzimidazoles as antiangiogenic agents;European Journal of Medicinal Chemistry;2014-11